BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» FDA says yes to Celgene’s Otezla in PsA: instead of ‘me-too’ drug, maybe ‘me-first’?
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
FDA says yes to Celgene’s Otezla in PsA: instead of ‘me-too’ drug, maybe ‘me-first’?
March 25, 2014
By
Randy Osborne
No Comments
With a label warning about weight loss that might actually help sales, Celgene Corp.’s oral phosphodieasterase-4 (PDE4) inhibitor Otezla (apremilast) was approved by the FDA on its Friday PDUFA date for adults with active psoriatic arthritis (PsA).
BioWorld